About: Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2) Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)
Creator	Jin, Zhao Kui, Zheng Chufang, Li Haiming, Jiang Jicheng, Huang Jun, Dai Lin, Wang Nanshan, Zhong Qinhai, Ma Runfeng, Li Shuxiang, Huang Weiqi, Pan Xiaobo, Li Xiaotao, Hou Yongxia, Shi Yunlong, Hou Zhenhua, Jia Zifeng, Yang
Source	Elsevier; Medline; PMC
abstract	Abstract Purpose Lianhuaqingwen (LH) as traditional Chinese medicine (TCM) formula has been used to treat influenza and exerted broad-spectrum antiviral effects on a series of influenza viruses and immune regulatory effects Ding et al. (2017). The goal of this study is to demonstrate the antiviral activity of LH against the novel SARS-CoV-2 virus and its potential effect in regulating host immune response. Methods The antiviral activity of LH against SARS-CoV-2 was assessed in Vero E6 cells using CPE and plaque reduction assay. The effect of LH on virion morphology was visualized under transmission electron microscope. Pro-inflammatory cytokine expression levels upon SARS-CoV-2 infection in Huh-7 cells were measured by real-time quantitative PCR assays. Results LH significantly inhibited SARS-CoV-2 replication in Vero E6 cells and markedly reduced pro-inflammatory cytokines (TNF-α, IL-6, CCL-2/MCP-1 and CXCL-10/IP-10) production at the mRNA levels. Furthermore, LH treatment resulted in abnormal particle morphology of virion in cells. Conclusions LH significantly inhibits the SARS-COV-2 replication, affects virus morphology and exerts anti-inflammatory activity in vitro. These findings indicate that LH protects against the virus attack, making its use a novel strategy for controlling the COVID-19 disease.
has issue date	2020-06-30(xsd:dateTime)
bibo:doi	10.1016/j.phrs.2020.104761
bibo:pmid	32205232
has license	els-covid
sha1sum (hex)	8ba7ca9fc65acc03c64948018ddcd5da54e94203
schema:url	https://doi.org/10.1016/j.phrs.2020.104761
resource representing a document's title	Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)
has PubMed Central identifier	PMC7102548
has PubMed identifier	32205232
schema:publication	Pharmacological Research
resource representing a document's body	covid:8ba7ca9fc65acc03c64948018ddcd5da54e94203#body_text
is schema:about of	named entity 'host' named entity 'virion' named entity 'antiviral' named entity 'treat' named entity 'virus' named entity 'making' named entity 'series' named entity 'COVID-19' named entity 'transmission electron microscope' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'Purpose' named entity 'SARS-CoV-2' named entity 'Vero' named entity 'activity' named entity 'antiviral' named entity 'TNF-α' named entity 'Huh' named entity 'antiviral' named entity 'influenza' named entity 'transmission electron microscope' named entity 'Vero E6' named entity 'morphology' named entity 'TNF-α' named entity 'mRNA' named entity 'SARS-COV-2' named entity 'pro-inflammatory cytokines' named entity 'SARS-CoV-2' named entity 'COVID-19 disease' named entity 'TCM' named entity 'virion' named entity 'MCP-1' named entity 'antiviral activity' named entity 'influenza' named entity 'coronavirus' named entity 'serum' named entity 'UPLC' named entity 'clinical study' named entity 'respiratory illness' named entity 'coronavirus' named entity 'remdesivir' named entity 'SARS-CoV-2' named entity 'remdesivir' named entity 'coronaviruses' named entity 'MCP-1' named entity 'cytotoxicity' named entity 'remdesivir' named entity 'public health' named entity 'biosafety level-3' named entity 'Vero E6' named entity 'antiviral' named entity 'virus replication' named entity 'anti-inflammatory' named entity 'SARS-CoV-2' named entity 'GCSF' named entity 'cytokines' named entity 'virus' named entity 'virus entry' named entity 'infection' named entity 'FBS' named entity 'cytokine storm' named entity 'respiratory illness' named entity 'inoculated' named entity 'pneumonia'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software